Fenoldopam and renal hemodynamics in shiga toxin-related hemolytic uremic syndrome

Background Fenoldopam, a vasodilating agent, may represent a potential therapeutic opportunity to increase renal perfusion in those conditions where renal hemodynamics are severely impaired by vascular sub-occlusion, as, indeed, is the case in thrombotic microangiopathies. Methods The renal resistan...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric nephrology (Berlin, West) West), 2021-09, Vol.36 (9), p.2891-2894
Main Authors: Ardissino, Gianluigi, Giussani, Antenore, Capone, Valentina, Testa, Sara, Gandini, Cristiano, Montini, Giovanni
Format: Article
Language:English
Subjects:
Brief Report
Child
Drug therapy
Escherichia coli Infections
Fenoldopam
Health aspects
Hemodynamics
Hemolytic uremic syndrome
Hemolytic-Uremic Syndrome - drug therapy
Humans
Ischemia
Kidneys
Medicine
Medicine & Public Health
Nephrology
Occlusion
Pediatrics
Perfusion
Shiga Toxin
Shiga-Toxigenic Escherichia coli
Urology
Vasodilators
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Fenoldopam, a vasodilating agent, may represent a potential therapeutic opportunity to increase renal perfusion in those conditions where renal hemodynamics are severely impaired by vascular sub-occlusion, as, indeed, is the case in thrombotic microangiopathies. Methods The renal resistance index (RRI) was measured, on and off fenoldopam, in 27 children with STEC-HUS. Results A 12% decrease in RRI was observed on fenoldopam compared to off treatment without changes in the systemic hemodynamics and with no side effects. Conclusions If confirmed in larger series, fenoldopam may become an important addition to supportive care to reduce ischemic damage in STEC-HUS and improve long-term outcomes.
ISSN:0931-041X
1432-198X
DOI:10.1007/s00467-021-05127-3